OMass Therapeutics Closes $310 Million Series C to Advance OMS1620 into Phase 2
Start here
OMass Therapeutics, an Oxford-based biotech developing small molecules against highly validated target ecosystems, has closed an oversubscribed $310 million (£230 million) Series C round. The funds will support development of OMS1620, a potential best-in-class MC2 (melanocortin-2) receptor antagonist, through Phase 2 studies in congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. The financing was announced on 15 October.
Excerpted from mp.weixin.qq.com
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comOMass Therapeutics Closes $310 Million Series C to Advance OMS1620 into Phase 2
OMass Therapeutics, an Oxford-based biotech developing small molecules against highly validated target ecosystems, has closed an oversubscribed $310 million (£230 million) Series C round. The funds will support development of OMS1620, a potential best-in-class MC2 (melanocortin-2) receptor antagonist, through Phase 2 studies in congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. The financing was announced on 15 October.
Heat trend for this story
Heat now 7·Peak in the comparable set 8（Oct 16 04:00）·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.